Home-based pulmonary rehabilitation has been slowly gaining momentum for chronic obstructive pulmonary disease (COPD), but ...

Canadian wildfire smoke has entered the Upper Midwest and poses significant health impacts in the hardest-hit areas.

Last fall, the hospital’s pharmacy team launched an effort aimed at cutting readmission rates for COPD, which are notoriously ...

Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Chronic obstructive pulmonary disease (COPD) affects millions of Americans, with new data from the National Center for Health Statistics showing the condition becomes increasingly common as people age ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...